+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Host defense against nontuberculous mycobacterial infections



Host defense against nontuberculous mycobacterial infections



Seminars in Respiratory Infections 11(4): 217-230



Human contact with the nontuberculous mycobacteria (NTM) is quite common, yet serious infections with these organisms were relatively infrequent until the advent of AIDS. Mycobacteria present an important window on the interaction of the innate (neutrophils, macrophages, NK cells) and acquired (T cells and B cells) immune systems. In their attempt to infect macrophages, the mycobacteria use their complex glycopeptidolipid cell wall to down-regulate macrophage responses. Once inside, mycobacteria are subject to the panoply of primary macrophage responses (e.g., vacuolar acidification, lytic enzymes). The infected macrophage produces cytokine signals (e.g., chemokines, interleukin [IL]-12] that recruit and stimulate lymphocytes from the innate (NK cell) and acquired (T and B cells) arms of the immune response to help kill the invading mycobacteria. Lymphocyte products that are central to the activation of macrophages to increased mycobacterial killing include tumor necrosis factor-alpha (TNF-alpha), interferon-gamma, and granulocyte-macrophage colony-stimulating factor (GM-CSF). The precise mechanisms by which these cytokines work remains unknown. Rare patients who have refractory disseminated NTM infection without HIV infection probably have underlying immune defects in critical pathways for control of mycobacteria. We have recently characterized one such family and found abnormal IL-12 regulation. Interferon-gamma, the cytokine primarily elicited by IL-12, has been used successfully with antimycobacterials for treatment of these patients. The window on the interaction of the innate and acquired immune systems that mycobacteria afford is being opened. Understanding the cell-cell interactions and cytokines involved in NTM infections will lead to new therapeutic approaches.

(PDF emailed within 1 workday: $29.90)

Accession: 046274768

Download citation: RISBibTeXText

PMID: 8976576


Related references

Host defense against mycobacterial infections--new strategies for combatting multidrug-resistant mycobacterial diseases. Nihon Saikingaku Zasshi. Japanese Journal of Bacteriology 52(2): 485-491, 1997

Host response to nontuberculous mycobacterial infections of current clinical importance. Infection and Immunity 82(9): 3516-3522, 2014

Nontuberculous mycobacteriosis; the present status and in the future. 3--(1). The view of development of new drugs against nontuberculous mycobacterial infections. Kekkaku 73(2): 77-82, 1998

Behaviour of gamma delta TCR+ T cells during the course of nontuberculous mycobacterial infections and proliferative response of host lymphocytes to 65kD heat shock protein. Kekkaku 68(2): 99-104, 1993

Role of antimicrobial peptides in host defense against mycobacterial infections. Peptides 29(10): 1836-1841, 2008

Neutrophil macrophage cooperation in the host defense against mycobacterial infections. Microbial Pathogenesis 6(5): 369-380, 1989

The role of nontuberculous mycobacterial skin test antigens in the diagnosis of mycobacterial infections. Chest 67(3): 320-324, 1975

Acquired and genetic host susceptibility factors and microbial pathogenic factors that predispose to nontuberculous mycobacterial infections. Current Opinion in Immunology 54: 66-73, 2018

Nontuberculous mycobacterial infections. Pediatric Infectious Disease Journal 11(10): 875-877, 1992

Nontuberculous mycobacterial infections. Zeitschrift für Rheumatologie 76(9): 752-760, 2017

Nontuberculous mycobacterial infections. Annals of PharmacoTherapy 30(7-8): 819-830, 1996

Nontuberculous mycobacterial infections. Medical Clinics of North America 81(2): 361-379, 1997

Nontuberculous mycobacterial infections. Archives of Pathology & Laboratory Medicine 132(8): 1333-1341, 2008

Nontuberculous mycobacterial infections of man. Medical Clinics of North America 58(3): 639-648, 1974

Nontuberculous mycobacterial infections in hematopoietic stem cell transplant recipients: characteristics of respiratory and catheter-related infections. Biology of Blood and Marrow Transplantation 6(4): 361-369, 2000